<DOC>
	<DOC>NCT01178827</DOC>
	<brief_summary>This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XRÂ®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.</brief_summary>
	<brief_title>Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Patient presents symptoms of overactive bladder Patient has age associated memory impairment No acute or unstable medical conditions History of alcohol or substance abuse within 1 year prior to study Has donated in excess of 500mL of blood or plasma in the 30 days prior to study Has known bleeding disorder (hemophilia) Previous abdominal bypass surgery for obesity</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>